Tuesday, April 3, 2018

MAVIRET (Glecaprevir/pibrentasvir) treats hepatitis C in HIV-coinfected individuals

Glecaprevir/pibrentasvir treats hepatitis C in HIV-coinfected individuals
Last Updated: 2018-04-02
By Reuters Staff
NEW YORK (Reuters Health) - The direct-acting antiviral (DAA) combination glecaprevir/pibrentasvir is effective for treating hepatitis C virus (HCV) infection in individuals coinfected with HIV-1, according to results from the non-randomized, open-label phase 3 EXPEDITION-2 trial. As many as 3 million of the 80 million individuals infected with HCV worldwide are coinfected with HIV-1. Most guidelines recommend these patients be treated like those with HCV monoinfection, with careful monitoring for drug-drug interactions with antiretroviral therapy (ART)....
Continue reading article: http://www.chronicliverdisease.org/reuters/article.cfm?article=20180402Other1554755267

No comments:

Post a Comment